Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Income Before Tax

Profit after all operating and non-operating items but before income tax.

Altimmune, Inc.NASDAQ: ALT

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$22.56M, compared with -$20.26M a year earlier. Trailing-twelve-month income before tax was -$91.08M.

Context

  • Income before tax amounted to 216522.0% of revenue in FY2025, down 258773.0 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$22.56M or moves back toward the trailing-twelve-month quarterly average of -$22.77M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.56M+17.5% QoQ
Last fiscal yearDec 2025
-$88.77M+6.6% YoY
LTMMar 2026
-$91.08M-0.2% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.4%——
1 year+6.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(88.77M) USD
Year-over-year change
+6.6%

Income Before Tax vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.2% is the 6th highest of 9, against a peer median of +30.5%.
  • Income before tax amounts to 253002.8% of revenue for ALT, versus a peer median of 89.4%.
ALT Competitors
Income Before Tax for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$160.72M USD+309.9%—84.0%
ASMBAssembly Biosciences, Inc.LTM Mar 2026-$6.38M USD+83.8%—9.0%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026-$18.86M USD-19.7%——
BMEABiomea Fusion, Inc.LTM Mar 2026-$44.95M USD+65.1%——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$61.89M USD+37.4%—89.4%
ALTAltimmune, Inc.LTM Mar 2026-$91.08M USD-0.2%—253002.8%
GPCRStructure Therapeutics Inc.LTM Jun 2026-$214.36M USD-20.1%——
IVAInventiva S.A.FY2025-€342.33M EUR-86.1%—7636.1%
VIRVir Biotechnology, Inc.LTM Mar 2026-$442.35M USD+23.6%—675.4%
Peer median (excluding ALT) —+30.5%—89.4%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.